Open Clinical Trials
Clinical Cardiac Research
Please find our current and upcoming studies, and their Principal Investiagtors, listed below:
Heart Failure | Joshua M. Larned, MD
TIMI DAPA ACT: A Multicenter, Randomized, DB, Parallel Group, Pbo Controlled Trial to evaluate the effect of in-hospital initiation of Dapagliflozin on clinical outcomes in patients who have been stabilized during hospitalization for Acute HF.
Heart Failure with Preserved Ejection Fraction | Joshua M. Larned, MD
AIM HIGHER ACE-HFpEF: Impulse Dynamics- The study will be a prospective, randomized, double-blinded, sham-controlled study of the safety and effectiveness of cardiac contractility modulation (CCM) therapy in subjects with symptomatic heart failure.
Heart Failure with Reduced Ejection Fraction | Joshua M. Larned, MD
MERCK- VICTOR: A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat/MK-1242 in Adults with Stable Heart Failure with Reduced Ejection Fraction.
Heart Failure With Reduced Ejection Fraction / Joshua M. Larned, MD:
Bristol Myers Squibb: An opel -label, single-sequence Study to evaluate the Effect of Coadministration of Danicamtiv on the Pharmacokinetics of midazolam in Patients with Stable Heart Failure with Reduced Ejection Fraction.
Hypertrophic Obstructive Cardiomyopathy | Elias Collado, MD
CYTOKINETICS-SEQUOIA: A phase 3, multi-center , Randomized, Double-blind trial to Evaluate The Efficacy and Safety Of Aficamten Compared to Placebo In Adults With Symptomati Non-Obstructive Hypertrophic Cardiomyopathy.
Recent Acute ACS/ Joshua Purow, MD:
LIBREXIA-ACS: A Phase 3, Randomized, Double-Blind-Controlled, Event-driven Study to Demonstrate the Efficacy and Safety Of Milvexian, an Oral Factor Xia Inhibitor, After a Recent Acute Coronary Syndrome.
Contact Us
If you would like more information about our open clinical trials:
- Call 954-542-8400
- Email jmhvri@holy-cross.com